Diversified Trust’s Keros Therapeutics KROS Stock Holding History

Diversified Trust’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$133K	Buy	+11,651	New	+$127K	﹤0.01%	997

Other funds holding KROS

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Diversified Trust's KROS Position: Q3 2026 in Review

Diversified Trust opened a new position in Keros Therapeutics (KROS) in Q3 2026: 11,651 shares worth $133K. The stake represents ﹤0.01% of the portfolio and ranks #997 among its holdings.

57 funds tracked by Wall St. Rank hold KROS as of Q3 2026.

Diversified Trust held 11,651 shares of Keros Therapeutics worth $133K as of Q3 2026.
Keros Therapeutics was a new Diversified Trust position in Q3 2026.
Keros Therapeutics made up ﹤0.01% of Diversified Trust's portfolio in Q3 2026, its #997 holding.
57 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.

Based on Diversified Trust's 13F filing for Q3 2026, filed 6 Nov 2026.